secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0000950170-22-026346
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics raises ~$7.9M in private placement of common stock and warrants
--------------------------------------------------------------------------------

- Gross proceeds ~$7.9M from sale of ~7.36M shares and warrants at $1.08 per unit.
- Warrants exercisable after 6 months at $1.08/share, expire in 5 years.
- Proceeds to advance C. diff and type 1 diabetes pipeline and for working capital.
- Existing investors including T. Denny Sanford and new institutional investors participated.
- Brookline Capital Markets acted as exclusive placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/0000950170-22-026346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/sabs-20221206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer